Industry Mobile Menu Trigger Overview Experience Team Insights Subscribe to insights March 14, 2024 Client Update European Parliament approves AI Act On March 13, the European Parliament passed a draft of the Artificial Intelligence Act. The AI Act includes requirements f... March 7, 2024 Articles & Books Artificial intelligence in drug development Davis Polk partners David Bauer and Matt Bacal, counsel Samantha Lefland and law clerk Ted Talas authored “Artificial in... March 6, 2024 Webinar The AI revolution in drug development – Key legal considerations Davis Polk hosts a series of webinars focused on legal considerations for life sciences and healthcare companies. In this ... February 13, 2024 Client Update U.S. Patent Office issues guidance for AI-assisted inventions On February 12, 2024, the United States Patent and Trademark Office issued inventorship guidance for AI-assisted invention... December 27, 2023 Articles & Books What’s ahead when AI and intellectual property converge Davis Polk partner David Lisson and associate Serge Voronov authored “What’s ahead when AI and intellectual property c... November 29, 2023 Client Update Three steps for safeguarding trade secrets in the world of generative AI Generative artificial intelligence (generative AI) tools pose new risks to a company’s trade secrets. This client update... July 25, 2023 Articles & Books Important generative AI considerations in M&A Davis Polk partner and IP, Tech & Commercial Transactions head Frank Azzopardi, partners Matt Bacal and Pri Shah, and asso... July 5, 2023 Client Update Navigating generative AI in M&A transactions The recent rise of consumer and market interest in generative artificial intelligence (GAI) tools has spurred growing inte...
March 14, 2024 Client Update European Parliament approves AI Act On March 13, the European Parliament passed a draft of the Artificial Intelligence Act. The AI Act includes requirements f...
March 7, 2024 Articles & Books Artificial intelligence in drug development Davis Polk partners David Bauer and Matt Bacal, counsel Samantha Lefland and law clerk Ted Talas authored “Artificial in...
March 6, 2024 Webinar The AI revolution in drug development – Key legal considerations Davis Polk hosts a series of webinars focused on legal considerations for life sciences and healthcare companies. In this ...
February 13, 2024 Client Update U.S. Patent Office issues guidance for AI-assisted inventions On February 12, 2024, the United States Patent and Trademark Office issued inventorship guidance for AI-assisted invention...
December 27, 2023 Articles & Books What’s ahead when AI and intellectual property converge Davis Polk partner David Lisson and associate Serge Voronov authored “What’s ahead when AI and intellectual property c...
November 29, 2023 Client Update Three steps for safeguarding trade secrets in the world of generative AI Generative artificial intelligence (generative AI) tools pose new risks to a company’s trade secrets. This client update...
July 25, 2023 Articles & Books Important generative AI considerations in M&A Davis Polk partner and IP, Tech & Commercial Transactions head Frank Azzopardi, partners Matt Bacal and Pri Shah, and asso...
July 5, 2023 Client Update Navigating generative AI in M&A transactions The recent rise of consumer and market interest in generative artificial intelligence (GAI) tools has spurred growing inte...